Could not connect to DB: 1040: Too many connectionsCould not execute 'UPDATE pressrelease SET r_hits = r_hits+ 1, r_total_hits = r_total_hits+ 1, r_pub_hits = r_pub_hits+ 1, r_total_pub_hits = r_total_pub_hits+ 1 WHERE r_id = 217980' on database eurekalert: 2002: Can't connect to local MySQL server through socket '/tmp/mysql.sock' (2) Public release date: 30-Jul-2012 [ | E-mail | Share ]

Contact: Laura Bailey baileylm@umich.edu 734-647-1848 University of Michigan

ANN ARBOR, Mich.In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissuesmainly boneproved quicker, more effective and less invasive than traditional bone regeneration treatments.

Researchers from the University of Michigan School of Dentistry and the Michigan Center for Oral Health Research partnered with Ann Arbor-based Aastrom Biosciences Inc. in the clinical trial, which involved 24 patients who required jawbone reconstruction after tooth removal.

Patients either received experimental tissue repair cells or traditional guided bone regeneration therapy. The tissue repair cells, called ixmyelocel-T, are under development at Aastrom, which is a U-M spinout company.

"In patients with jawbone deficiencies who also have missing teeth, it is very difficult to replace the missing teeth so that they look and function naturally," said Darnell Kaigler, principal investigator and assistant professor at the U-M School of Dentistry. "This technology and approach could potentially be used to restore areas of bone loss so that missing teeth can be replaced with dental implants."

William Giannobile, director of the Michigan Center for Oral Health Research and chair of the U-M Department of Periodontics and Oral Medicine, is co-principal investigator on the project.

The treatment is best suited for large defects such as those resulting from trauma, diseases or birth defects, Kaigler said. These defects are very complex because they involve several different tissue typesbone, skin, gum tissueand are very challenging to treat.

The main advantage to the stem cell therapy is that it uses the patient's own cells to regenerate tissues, rather than introducing man-made, foreign materials, Kaigler said.

The results were promising. At six and 12 weeks following the experimental cell therapy treatment, patients in the study received dental implants. Patients who received tissue repair cells had greater bone density and quicker bone repair than those who received traditional guided bone regeneration therapy.

Follow this link:
Stem cell therapy could offer new hope for defects and injuries to head, mouth

ScienceDaily (July 30, 2012) Stem cells can actually replace dead heart tissue after a heart attack very early in life -- but those same cells lose that regenerative ability in adults, according to researchers at Cornell University and the University of Bonn.

The study, using mice as subjects, found that undifferentiated precursor cells grow new heart cells in a two-day-old mouse, but not in adult mice, settling a decades-old controversy about whether stem cells can play a role in the recovery of the adult mammalian heart following infarction -- where heart tissue dies due to artery blockage.

"While the existence of these cells in adults is controversial, if one did have fully capable stem cells in adults, why are there no new heart cells after an infarct? Whether this is due to a lack of stem cells or to something special about the infarct that inhibits stem cells from forming new heart cells is the question we addressed, taking advantage of the fact that the newborn mouse has these cells," said Michael Kotlikoff, dean of Cornell's College of Veterinary Medicine and senior author of the paper. The paper will appear Aug. 29 in the Proceedings of the National Academy of Sciences.

Kotlikoff and his fellow researchers found that two-day-old mice grew new heart cells and almost completely recovered from infarction, proving that the injury did not inhibit stem cells from growing new heart cells. The same procedure was carried out on adult mice and no new heart cells formed, confirming that adults do not have the requisite stem cells to create new heart cells, called myocytes, though new blood vessel cells were created.

The stem cells found in the adult heart "have lost the ability to become heart cells, and are only capable of forming new vessels," Kotlikoff said. Single stem cells differentiate into all tissues at the start of life, but over time these cells become "developmentally restricted" or specialized to form only certain tissues.

Sophie Jesty, Michele Steffey, and Frank Lee are the paper's lead authors and the work is part of a long-term collaboration with Professor Bernd Fleischmann's team at the University of Bonn.

The study was funded by the National Institutes of Health, New York State Stem Cell Science and the European Union Seventh Framework Programme.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

See the original post:
Stem cells repair hearts early in life, but not in adults

ITHACA, N.Y., July 31 (UPI) -- Stem cells can replace dead heart tissue after a heart attack very early in life, but they lose that ability in adults, U.S. and German researchers say.

Senior author Michael Kotlikoff, dean of Cornell's College of Veterinary Medicine, and colleagues at the University of Bonn said the study involving mice found undifferentiated precursor cells grow new heart cells in a 2-day-old mouse, but not in adult mice.

Kotlikoff said the finding settles a decades-old controversy about whether stem cells can play a role in the recovery of the adult mammalian heart following infarction -- in which heart tissue dies due to artery blockage.

"While the existence of these cells in adults is controversial, if one did have fully capable stem cells in adults, why are there no new heart cells after an infarct? Whether this is due to a lack of stem cells or to something special about the infarct that inhibits stem cells from forming new heart cells is the question we addressed, taking advantage of the fact that the newborn mouse has these cells," Kotlikoff said in a statement.

The study, scheduled to be published in the August issue of the Proceedings of the National Academy of Sciences, found that 2-day-old mice grew new heart cells and almost completely recovered from infarction, proving that the injury did not inhibit stem cells from growing new heart cells.

The rest is here:
Stem cells repair heart only early in life

A US federal court rules that procedures in which a patients own stem cells are extracted, manipulated, and reinjected should be regulated by the FDA.

By Bob Grant | July 30, 2012

Leonardini | stock.xchng

After years of legal wrangling, the US District Court in Washington, DC, last week upheld the Food and Drug Administrations power to regulate adult stem cell treatments in which the cells are more than minimally manipulated before being injected back into the patient. The court ruled that the FDA was operating within its legal mandate when it filed suit against Colorado-based stem cell treatment clinic Regenerative Sciences in 2010 to stop them from extracting, processing, and then reinjecting patients own bone marrow stem cells to treat bone and joint disorders.

The FDA argued that the treatment fell under its purview and was subject to approval like any new drug because the extracted cells were significantly modified using reagents that cross state lines. Regenerative Sciences disagreed, characterizing the treatment as a simple medical procedure, which dont require FDA approval. The court sided with the FDA, making similar stem cell clinics popping up in the United States take notice. University of Minnesota bioethicist Leigh Turner told Nature that the ruling was spot on. It is much too simplistic to think that stem cells are removed from the body and then returned to the body without a manufacturing process that includes risk of transmission of communicable diseases, he said. Maintaining the FDAs role as watchdog and regulatory authority is imperative.

But Chris Centeno, Regenerative Sciences medical director told Nature that the clinic plans to continue offering patients 3 of its 4 stem cell treatments, in which cells are only processed for 2 days before reinjection. He added that the company will continue to treat patients using the process now prohibited by the FDA in a clinic located in the Cayman Islands and that Regenerative Sciences plans to appeal the courts ruling.

By Edyta Zielinska

The National Institutes of Health will fund 17 projects developing lab-on-a-chip applications to improve drug screening.

By Cristina Luiggi

After treating terminally ill patients with an unauthorized experimental probiotic procedure, two California doctors can no longer participate in human research.

Excerpt from:
Stem Cell Treatment = Drug

July 30, 2012

Stem cells create new heart cells in baby mice, but not in adults, study shows

Kotlikoff Lab

In a two-day-old mouse, a heart attack causes active stem cells to grow new heart cells; a few months later, the heart is mostly repaired. But in an adult mouse, recovery from such an attack leads to classic after-effects: scar tissue, permanent loss of function and life-threatening arrhythmias.

A new study by Cornell and University of Bonn researchers found that stem cells did not create new heart cells in adult mice after a heart attack, settling a decades-old controversy about whether stem cells play a role in the recovery of the adult mammalian heart following infarction -- the leading cause of sudden death in the developed world -- where heart tissue dies due to artery blockage.

"If you did have fully capable stem cells in adults, why are there no new heart cells after an infarct? And is this due to the lack of stem cells or due to something special about the infarct that inhibits stem cells from forming new heart cells?" asked Michael Kotlikoff, the Austin O. Hooey Dean of Cornell's College of Veterinary Medicine, and senior author of the paper appearing Aug. 29 in the Proceedings of the National Academy of Sciences.

Beating heart cells

This movie shows beating heart cells in culture that originated as stem cells (look closely around the center of the frame). The researchers used a mouse model where heart cells fluoresced red and undifferentiated stem cells fluoresced green. All of the cells shown in the movie were green at the time of culture and they turn red after they become heart cells. There were no red cells to start, indicating that the origin of the beating red cells was green stem cells. Watch video

Co-author Michelle Steffey, a small-animal surgeon in Cornell's veterinary college, developed a procedure to infarct a neonatal mouse heart that is only one-tenth-of-an-inch wide. "It was a tour-de-force technically to infarct and recover those baby mice," said Kotlikoff.

The baby mice grew new heart cells and almost completely recovered from infarction, proving that the infarction did not inhibit stem cells from growing new heart cells. The same procedure was carried out on adult mice and no new heart cells formed, confirming that adults do not have the requisite stem cells to create new heart cells, called myocytes, though new blood vessel cells were created.

Continue reading here:
Stem cells create new heart cells in baby mice, but not in adults, study shows